Landscape of toxin-neutralizing therapeutics for snakebite envenoming (2015–2022): setting the stage for an R&D agenda

 

Enregistré dans:
Détails bibliographiques
Auteurs: Borri, Juliette, Gutiérrez, José María, Knudsen, Cecilie, Habib, Abdulrazaq G., Goldstein, Maya, Tuttle, Andrew
Format: artículo original
Date de publication:2024
Description:Snakebite envenoming (SBE) is a neglected tropical disease that exerts a high impact worldwide, especially in sub-Saharan Africa, Asia, and Latin America. Animal-derived antivenoms constitute the only specific, scientifically validated treatment for envenomings, although new therapeutic alternatives are being pursued. Despite the relevance of this disease, there is a critical lack of data on the research and development landscape in antivenoms and novel therapeutics. This study describes a thorough search of the state of SBE therapeutic market and research pipeline. A total of 127 marketed products and 196 candidates were identified. The current antivenom landscape is characterised by a homogeneous market of similar but geographically bespoke products needing improvement. The R&D pipeline analysis component revealed a diverse but immature picture since only eight candidates are in clinical development. This article interprets the findings of the study to provide an initial list of priority areas that sets the stage for further development of an R&D agenda to ensure translation of innovation to reduce the impact of SBE.
Pays:Kérwá
Institution:Universidad de Costa Rica
Repositorio:Kérwá
Langue:Inglés
OAI Identifier:oai:kerwa.ucr.ac.cr:10669/104882
Accès en ligne:https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0012052
https://hdl.handle.net/10669/104882
https://doi.org/10.1371/journal.pntd.0012052
Mots-clés:Snakebite envenoming (SBE)
Neglected tropical disease
Global impact
Sub-Saharan Africa
Asia
Latin America
Animal-derived antivenoms
Specific treatment